SVE
ENG
Initial public offering and listing on Nasdaq First North Stockholm Period July – September 2016 Revenues amounted to MSEK 0.0 (0.0) Operating result amounted to MSEK -6.6 (-7.5) Result after…
November 3, 2016 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
